Document Detail

Disruption of Nox2 and TNFRp55/p75 eliminates cardioprotection induced by anisomycin.
MedLine Citation:
PMID:  22982779     Owner:  NLM     Status:  MEDLINE    
Transient activation of p38 through anisomycin is demonstrated to precondition the heart against myocardial injury. However, it remains unknown whether specific TNF-α receptor (TNFR) p55/p75 and Nox2, a subunit of NADPH oxidase, are involved in this event. We sought to investigate whether the genetic disruption of TNFRp55/p75 and Nox2 eliminated cardioprotection elicited by anisomycin and whether p38-dependent activation of Nox2 stimulated TNFR to ultimately achieve protective effects. Adult wild-type and TNFR p55/p75(-/-) and Nox2(-/-) mice received intraperitoneal injections of anisomycin (0.1 mg/kg), a potent activator of p38. The hearts were subjected to 30 min myocardial ischemia/30 min reperfusion in the Langendorff perfused heart after 24 h. Left ventricular function was measured, and infarct size was determined. Myocardial TNF-α protein, Nox2, and superoxides releases were detected. Gel kinase assay was employed to detect the effect of p38 on Nox2 phosphorylation. Activation of p38 through anisomycin produces marked improvements in left ventricular functional recovery, and the reduction of myocardial infarction, which were abrogated by disruption of Nox2 and TNFR p55/p75. Disruption of Nox2 and TNFR p55/p75 abolished the effect of anisomycin-induced reduction of infarct size. Anisomycin induced the production of TNF-α, which was abrogated in Nox2(-/-) mice and by treatment with SB203580, but not by disruption of p55/p75. Anisomycin treatment resulted in an increase in Nox2 protein and the phosphorylation of Nox2, which was blocked by inhibition of p38. Taken together, these results indicate that stimulation of the Nox2 and TNFR p55/p75 pathway is a novel approach to anisomycin-induced cardioprotection.
Ting C Zhao; Ling Zhang; Jun T Liu; Tai L Guo
Related Documents :
12173819 - Stroke after conventional versus minimally invasive coronary artery bypass.
9813529 - Jugular venous desaturation following cardiac surgery.
23567879 - Modified technique for coronary artery ligation in mice.
9568449 - Long-term clinical outcome following coronary artery bypass grafting for isolated steno...
22585639 - Sudden cardiac death of rhythmic origin in athletes: literature review.
12683569 - Off-pump technique for the treatment of ventricular myocardial echinococcosis.
2992989 - Emission tomography with 99mtc-pyrophosphate in the diagnosis of acute myocardial infar...
23198389 - History and use of del nido cardioplegia solution at boston children's hospital.
11720639 - Dalteparin for acute coronary syndromes.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-09-14
Journal Detail:
Title:  American journal of physiology. Heart and circulatory physiology     Volume:  303     ISSN:  1522-1539     ISO Abbreviation:  Am. J. Physiol. Heart Circ. Physiol.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-16     Completed Date:  2013-01-17     Revised Date:  2013-12-04    
Medline Journal Info:
Nlm Unique ID:  100901228     Medline TA:  Am J Physiol Heart Circ Physiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  H1263-72     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anisomycin / administration & dosage,  pharmacology*
Disease Models, Animal
Enzyme Activation
Enzyme Activators / administration & dosage,  pharmacology*
Injections, Intraperitoneal
Membrane Glycoproteins / deficiency,  genetics,  metabolism*
Mice, Inbred C57BL
Mice, Knockout
Myocardial Infarction / drug therapy*,  metabolism,  pathology,  physiopathology
Myocardial Reperfusion Injury / drug therapy*,  metabolism,  pathology,  physiopathology
Myocardium / metabolism*,  pathology
NADPH Oxidase / deficiency,  genetics,  metabolism*
Protein Kinase Inhibitors / pharmacology
Receptors, Tumor Necrosis Factor, Type I / deficiency,  genetics,  metabolism*
Receptors, Tumor Necrosis Factor, Type II / deficiency,  genetics,  metabolism*
Signal Transduction / drug effects
Superoxides / metabolism
Time Factors
Tumor Necrosis Factor-alpha / metabolism
Ventricular Function, Left / drug effects
p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors,  metabolism
Grant Support
Reg. No./Substance:
0/Enzyme Activators; 0/Membrane Glycoproteins; 0/Protein Kinase Inhibitors; 0/Receptors, Tumor Necrosis Factor, Type I; 0/Receptors, Tumor Necrosis Factor, Type II; 0/Tnfrsf1a protein, mouse; 0/Tumor Necrosis Factor-alpha; 11062-77-4/Superoxides; 6C74YM2NGI/Anisomycin; EC protein, mouse; EC Oxidase; EC Mitogen-Activated Protein Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Preconditioning protects the heart in a prolonged uremic condition.
Next Document:  Sex differences in mesenteric endothelial function of streptozotocin-induced diabetic rats: a shift ...